Otsuka non-interventional: Recent Onset SZ Survey
Research type
Research Study
Full title
Patient Preferences in Recent Onset Schizophrenia
IRAS ID
209656
Contact name
Jesus Perez
Contact email
Sponsor organisation
Otsuka Pharmaceuticals Europe Ltd.
Clinicaltrials.gov Identifier
TFS Internal study number, OTS0005
Duration of Study in the UK
0 years, 3 months, 1 days
Research summary
Schizophrenia is a long-term psychiatric illness which can cause distressing psychological symptoms including hallucinations and delusions, and cognitive symptoms including problems with memory, attention, concentration and managing social interactions. The current treatments for schizophrenia, the anti-psychotic medications, help with the psychotic symptoms however, one of the major challenges healthcare professionals and patients face are the choice of treatment in schizophrenia, as it may take a trial of different medications to find which works best for an individual, and approximately 50-75% of patients discontinue their medication.
The focus of the study is to find out what type of treatment goals and outcomes patients who suffer with schizophrenia prefer, and which symptoms of the illness patients see as the most important to treat. This study will examine patient preferences for key outcomes (what patients want to get out of their medication) associated with schizophrenia treatments through the completion of a patient survey. The survey is designed to quantify which treatment outcomes are the most important to patients and which type of treatment patients prefer taking (oral or injection).
The study will take place in 3 countries in Europe with the aim of recruiting 100 patients who have been diagnosed with schizophrenia within 5 years, in a stable clinical condition and have been prescribed an anti-psychotic treatment for at least 6 months.
Patients will be asked to complete the patient survey on key outcomes and treatment preferences during a routine visit to their normal clinic. Patient participation in the study will last for that single visit.The study is observational and, consequently, all treatment decisions are at discretion of the patients health care provider and are not mandated by study design or protocol.
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
16/WM/0348
Date of REC Opinion
12 Aug 2016
REC opinion
Further Information Favourable Opinion